Ownership of Aadi Bioscience (now operating as Whitehawk Therapeutics following its corporate acquisition and transition) is distributed among institutional asset management firms, venture capital funds, and specialized life sciences investment groups. Major institutional stakeholders historically holding significant equity positions include institutional healthcare funds, specialized biotech investors, and corporate insiders who guided its clinical trials and strategic transaction with Kaken Pharmaceutical Co., Ltd.